Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in Foster City, California.
IPO Year: 2020
Exchange: NASDAQ
Website: vaxcyte.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/22/2025 | Overweight | Cantor Fitzgerald | |
| 12/20/2024 | $135.00 | Buy | Goldman |
| 12/7/2023 | $69.00 | Buy | Mizuho |
| 4/18/2023 | Outperform | TD Cowen | |
| 1/3/2023 | $52.00 → $58.00 | Buy | Needham |
| 12/15/2022 | $66.00 | Buy | Guggenheim |
| 11/17/2022 | $69.00 | Buy | BTIG Research |
| 12/29/2021 | $50.00 | Buy | Jefferies |
| 6/24/2021 | $50.00 | Buy | Jefferies |